245 related articles for article (PubMed ID: 25356878)
1. Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis.
Liao KL; Bai XF; Friedman A
PLoS One; 2014; 9(10):e110126. PubMed ID: 25356878
[TBL] [Abstract][Full Text] [Related]
2. Mathematical modeling of interleukin-27 induction of anti-tumor T cells response.
Liao KL; Bai XF; Friedman A
PLoS One; 2014; 9(3):e91844. PubMed ID: 24633175
[TBL] [Abstract][Full Text] [Related]
3. The role of the cytokines IL-27 and IL-35 in cancer.
Friedman A; Liao KL
Math Biosci Eng; 2015 Dec; 12(6):1203-17. PubMed ID: 26775857
[TBL] [Abstract][Full Text] [Related]
4. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
5. IL-23 promotes tumour incidence and growth.
Langowski JL; Zhang X; Wu L; Mattson JD; Chen T; Smith K; Basham B; McClanahan T; Kastelein RA; Oft M
Nature; 2006 Jul; 442(7101):461-5. PubMed ID: 16688182
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML
Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680
[TBL] [Abstract][Full Text] [Related]
7. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis.
Wang Z; Liu JQ; Liu Z; Shen R; Zhang G; Xu J; Basu S; Feng Y; Bai XF
J Immunol; 2013 Mar; 190(5):2415-23. PubMed ID: 23345334
[TBL] [Abstract][Full Text] [Related]
8. Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies.
Gelfo V; Romaniello D; Mazzeschi M; Sgarzi M; Grilli G; Morselli A; Manzan B; Rihawi K; Lauriola M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825489
[TBL] [Abstract][Full Text] [Related]
9. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress.
Ito K; Scott SA; Cutler S; Dong LF; Neuzil J; Blanchard H; Ralph SJ
Angiogenesis; 2011 Sep; 14(3):293-307. PubMed ID: 21523436
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
11. Swords into plowshares: IL-23 repurposes tumor immune surveillance.
Langowski JL; Kastelein RA; Oft M
Trends Immunol; 2007 May; 28(5):207-12. PubMed ID: 17395538
[TBL] [Abstract][Full Text] [Related]
12. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
13. Tumor-related interleukins: old validated targets for new anti-cancer drug development.
Setrerrahmane S; Xu H
Mol Cancer; 2017 Sep; 16(1):153. PubMed ID: 28927416
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6: an angiogenic target in solid tumours.
Middleton K; Jones J; Lwin Z; Coward JI
Crit Rev Oncol Hematol; 2014 Jan; 89(1):129-39. PubMed ID: 24029605
[TBL] [Abstract][Full Text] [Related]
15. IL-35 induces N2 phenotype of neutrophils to promote tumor growth.
Zou JM; Qin J; Li YC; Wang Y; Li D; Shu Y; Luo C; Wang SS; Chi G; Guo F; Zhang GM; Feng ZH
Oncotarget; 2017 May; 8(20):33501-33514. PubMed ID: 28432279
[TBL] [Abstract][Full Text] [Related]
16. Targeting interleukin-22 for cancer therapy.
Markota A; Endres S; Kobold S
Hum Vaccin Immunother; 2018; 14(8):2012-2015. PubMed ID: 29617184
[TBL] [Abstract][Full Text] [Related]
17. IL-26 promotes the pathogenesis of malignant pleural effusion by enhancing CD4
Niu Y; Ye L; Peng W; Wang Z; Wei X; Wang X; Li Y; Zhang S; Xiang X; Zhou Q
J Leukoc Biol; 2021 Jul; 110(1):39-52. PubMed ID: 33847412
[TBL] [Abstract][Full Text] [Related]
18. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.
Olson BM; Jankowska-Gan E; Becker JT; Vignali DA; Burlingham WJ; McNeel DG
J Immunol; 2012 Dec; 189(12):5590-601. PubMed ID: 23152566
[TBL] [Abstract][Full Text] [Related]
19. Regulation of angiostatic chemokines driven by IL-12 and IL-27 in human tumors.
Airoldi I; Ribatti D
J Leukoc Biol; 2011 Nov; 90(5):875-82. PubMed ID: 21750124
[TBL] [Abstract][Full Text] [Related]
20. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.
Wigginton JM; Gruys E; Geiselhart L; Subleski J; Komschlies KL; Park JW; Wiltrout TA; Nagashima K; Back TC; Wiltrout RH
J Clin Invest; 2001 Jul; 108(1):51-62. PubMed ID: 11435457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
